- PRODUODOPA® is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson s disease
- PRODUODOPA demonstrated sustained.
Moberg Pharma´s Interim report January - June 2023MOB-015 IS RECOMMENDED FOR APPROVAL IN 13 EUROPEAN COUNTRIES SIX-MONTH PERIOD (JAN-JUN 2023)· EBITDA SEK -10.7 million (-9.1)· Operating profit (EBIT) SEK -12.0 million (-10.4)&middo.
/PRNewswire/ Moberg Pharma AB (OMX: MOB) hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended.
MOB-015 is recommended for approval in EU realtid.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from realtid.se Daily Mail and Mail on Sunday newspapers.